MX2024007054A - Aglutinantes de mesotelina humana. - Google Patents

Aglutinantes de mesotelina humana.

Info

Publication number
MX2024007054A
MX2024007054A MX2024007054A MX2024007054A MX2024007054A MX 2024007054 A MX2024007054 A MX 2024007054A MX 2024007054 A MX2024007054 A MX 2024007054A MX 2024007054 A MX2024007054 A MX 2024007054A MX 2024007054 A MX2024007054 A MX 2024007054A
Authority
MX
Mexico
Prior art keywords
human mesothelin
binders
mesothelin binders
human
antigen
Prior art date
Application number
MX2024007054A
Other languages
English (en)
Spanish (es)
Inventor
Arthur Fridman
Chung - Ming HSIEH
Masahisa Handa
Sujata Singh
Sahba Tabrizifard
Sandra Isabel Vanegas
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2024007054A publication Critical patent/MX2024007054A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2024007054A 2021-12-10 2022-12-09 Aglutinantes de mesotelina humana. MX2024007054A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163288162P 2021-12-10 2021-12-10
PCT/US2022/081253 WO2023108114A2 (en) 2021-12-10 2022-12-09 Human mesothelin binders

Publications (1)

Publication Number Publication Date
MX2024007054A true MX2024007054A (es) 2024-09-04

Family

ID=86731328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007054A MX2024007054A (es) 2021-12-10 2022-12-09 Aglutinantes de mesotelina humana.

Country Status (8)

Country Link
EP (1) EP4444757A4 (enExample)
JP (1) JP2025501452A (enExample)
KR (1) KR20240114766A (enExample)
CN (1) CN118660911A (enExample)
AU (1) AU2022407541A1 (enExample)
CA (1) CA3239553A1 (enExample)
MX (1) MX2024007054A (enExample)
WO (1) WO2023108114A2 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2195017T1 (sl) * 2007-10-01 2015-01-30 Bristol-Myers Squibb Company Človeška protitelesa, ki vežejo mezotelin in njihova uporaba
PE20170917A1 (es) * 2010-12-20 2017-07-12 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CA3063362A1 (en) * 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
CN114008071B (zh) * 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
WO2020205849A1 (en) * 2019-04-01 2020-10-08 Lakepharma, Inc. Btla-binding (cd272) antibodies for modulating immune response and treating disease

Also Published As

Publication number Publication date
JP2025501452A (ja) 2025-01-22
EP4444757A2 (en) 2024-10-16
WO2023108114A2 (en) 2023-06-15
CA3239553A1 (en) 2023-06-15
CN118660911A (zh) 2024-09-17
KR20240114766A (ko) 2024-07-24
WO2023108114A3 (en) 2024-04-04
EP4444757A4 (en) 2026-04-15
AU2022407541A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
SA520420631B1 (ar) الأجسام المضادة لـ cd3 واستخداماتها
MX2025000260A (es) Proteina de union al antigeno anti-steap1
ZA201906004B (en) Anti-par2 antibodies and uses thereof
PH12021500031A1 (en) Anti-il2 receptor gamma antigen-binding proteins
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
PH12022550348A1 (en) Materials and methods for improved single chain variable fragments
MX2020012905A (es) Proteínas de unión multiespecíficas y mejoras con estas.
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
DK3638698T3 (da) Anti-TMPRSS2-antistoffer og antigenbindingsfragmenter
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
MX2021007093A (es) Anticuerpos btla.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
ZA202309150B (en) Antibody against nkp46 and application of antibody
HRP20260098T1 (hr) Anti-gprc5d monoklonska protutijela i njihova upotreba
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
MX2024014547A (es) Anticuerpos anti-bcma
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.